
|Videos|October 18, 2013
Ipilimumab in the Adjuvant Setting for Melanoma
Author(s)Vernon K. Sondak, MD
Vernon K. Sondak, MD, chair of the Department of Cutaneous Oncology at Moffitt Cancer Center, discusses the use of ipilimumab in the adjuvant setting for patients with melanoma.
Advertisement
Clinical Pearls
Vernon K. Sondak, MD, chair of the Department of Cutaneous Oncology at Moffitt Cancer Center, discusses the use of ipilimumab in the adjuvant setting for patients with melanoma.
- There are a number of studies looking at ipilimumab in the adjuvant setting
- There has been a fair amount of toxicity associated with the 10-mg/kg dosage
- Adjuvant therapy with ipilimumab outside of a clinical trial is not recommended
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































